October 12, 2020

Vigene Strengthens Management Team Critical Execut...

Vigene Biosciences announces today an executive addition. Molly McGlaughlin is appointed as Chief Operation Officer.
October 9, 2020

Rznomics Announces Manufacturing Agreement with Vi...

Vigene has entered a contract manufacturing agreement with Rznomics Inc. for its leading pipeline product, RZ-001. RZ-001 is a gene therapy for advanced hepatocellular carcinoma (HCC).
August 31, 2020

Vigene Biosciences made the 2020 Inc. 5000 list of...

Vigene Biosciences made the 2020 Inc. 5000 list of the fastest-growing private companies in America!
July 22, 2020

Altimmune Announces Manufacturing Agreement with V...

Vigene entered an agreement with Altimmune to manufacture its single-dose intranasal vaccine candidate for COVID-19.
June 4, 2020

Vigene Biosciences Awarded Patent for improvements...

The modifications on AAV vector leads to 2-4 folds increase in production yield.
February 27, 2020

Vigene Biosciences Awarded Patent for improvements...

ROCKVILLE, Md. – February 24, 2020 – Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and […]
February 27, 2020

Vigene and ASC Therapeutics Announce Long-Term Str...

ROCKVILLE, Md. Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development for cell and gene […]
February 27, 2020

Vigene Biosciences Opens State-Of-The-Art Headquar...

ROCKVILLE, MD – January 29, 2020 – Vigene Biosciences, Inc. (Vigene), a pioneer in the viral gene delivery space, unveils […]
February 27, 2020

Vigene Biosciences Secures Institutional Investmen...

Rockville, MD. – April 29, 2019 – Vigene Biosciences, Inc (“Vigene”) a leading provider of viral vector products and services […]
December 18, 2018

Vigene Biosciences announces partnership with Viro...

ROCKVILLE, Md. Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, announced today that the […]